PALMA DE MALLORCA, Spain, April 4, 2011 /PRNewswire/ -- The Board of Directors of Global Immune Technologies, Inc. (OTC QB: GIMU) announces that it has executed an agreement to provide the Company with a $50 million financing package and engages financial consultants Arcis International Trust, S.A. (www.arcis-trust.com) to achieve these goals. Arcis International Trust, S.A. is a leading information and global opportunity provider with a goal to inform and assist their clients worldwide.
Company co-founder and director, Chief of R&D, Uwe Vincenz says, "We are extremely proud and excited to be represented by this prestigious group. Arcis is well known globally and have performed well for many clients. We can now move forward with speed and certainty knowing they will accomplish the necessary funding for our project." In addition to Arcis Trust having raised over a billion dollars in project funding they have a social commitment towards communities in need of resources to be able to develop and grow properly. Arcis devotes a lot of energy, time and resources to humanitarian causes. Our solar efforts fit right into those ideals.
Further information can be obtained by telephoning the Company at +1 406 558 4947 email@example.com or by visiting www.renewunlimited.com or Uwe Vincenz, Telefon: +49 3447 834448 www.iat-remsa.de or email: firstname.lastname@example.org
Safe Harbour Statement
This communication contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Global Immune Technologies, Inc. and members of its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully, and the ability to complete before-mentioned transactions.
The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE Global Immune Technologies, Inc.